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Abstract
Background: Interleukin-10 (IL-10) is a cytokine whose main biological function is to suppress the
immune response by induction of a signal(s) leading to inhibition of synthesis of a number of
cytokines and their cellular receptors. Signal transduction is initiated upon formation of a ternary
complex of IL-10 with two of its receptor chains, IL-10R1 and IL-10R2, expressed on the cell
membrane. The affinity of IL-10R1 toward IL-10 is very high, which allowed determination of the
crystal structure of IL-10 complexed with the extracellular/soluble domain of IL-10R1, while the
affinity of IL-10R2 toward either IL-10 or IL-10/sIL-10R1 complex is quite low. This so far has
prevented any attempts to obtain structural information about the ternary complex of IL-10 with
its receptor chains.
Results: Structures of the second soluble receptor chain of interleukin-10 (sIL-10R2) and the
ternary complex of IL-10/sIL-10R1/sIL-10R2 have been generated by homology modeling, which
allowed us to identify residues involved in ligand-receptor and receptor-receptor interactions.
Conclusion:  The previously experimentally determined structure of the intermediate/binary
complex IL-10/sIL-10R1 is the same in the ternary complex. There are two binding sites for the
second receptor chain on the surface of the IL-10/sIL-10R1 complex, involving both IL-10 and sIL-
10R1. Most of the interactions are hydrophilic in nature, although each interface includes two
internal hydrophobic clusters. The distance between C-termini of the receptor chains is 25 Å,
which is common for known structures of ternary complexes of other cytokines. The structure is
likely to represent the biologically active signaling complex of IL-10 with its receptor on the surface
of the cell membrane.
Background
IL-10 is a pleiotropic cytokine (reviewed in [1,2]) that
suppresses immune system response by inhibiting synthe-
sis of proinflammatory cytokines and their cellular recep-
tors [3,4]. In addition to immunosuppressive functions,
IL-10 also possesses immunostimulatory activities,
including stimulation of growth and proliferation of
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thymocytes, cytokine-activated T-cells, mast cells, and B-
cells [5-9].
Signal transduction is initiated when IL-10 binds to its cel-
lular receptor, which consists of two chains, IL-10R1 and
IL-10R2. IL-10 is an intercalated dimer made of two iden-
tical polypeptides, each 160 amino acids long [10-12],
packed in two compact, six-helix bundle domains
(reviewed in [2,13-15]). The domains are related by a two-
fold symmetry axis passing through the interdomain
interface. Both receptor chains have about a 200 amino
acids-long extracellular domain, a 20 amino acids-long
transmembrane helix, and an intracellular/cytoplasmic
domain, which contains 322 or 62 amino acids for IL-
10R1 and IL-10R2, respectively. When the ternary com-
plex IL-10/IL-10R1/IL-10R2 is formed, tyrosine kinases
Tyk2 and Jak1 become activated and phosphorylate spe-
cific tyrosine residues on signal transducers and activators
of transcription, which eventually leads to activation of
the transcription of corresponding genes [16,17]. Kinetic
binding data on soluble IL-10 receptor chains (sIL-10R)
showed that sIL-10R1 exhibits nanomolar binding con-
stants for IL-10, while sIL-10R2 does not display any sig-
nificant affinity for IL-10, although binding of sIL-10R2 to
a preformed binary IL-10/sIL-10R1 complex is noticeably
better [18]. It has been commonly accepted that at first IL-
10 binds to its high affinity receptor IL-10R1, forming a
binding site for IL-10R2, and then the binding of the latter
receptor finalizes the ternary signaling complex. It has
been also shown for the IFN-(/receptor complex, which is
likely to be similar to the IL-10 complex, that under phys-
iological conditions the receptor chains are already preas-
sembled together, even before the ligand binds. Thus,
binding of the ligand is necessary only for opening the
intracellular domain regions to accommodate intracellu-
lar components of the downstream signal transduction
pathway [19]. It was shown for IL-19 and IL-20, which
also belong to the IL-10 family, that their final ternary
complexes with the soluble receptors are very much alike,
no matter what was the order of binding components in
solution [20]. Therefore, the structure of the ternary IL-10/
sIL-10R1/sIL-10R2 complex can be predicted on the basis
of the structures of the intermediate binary complex IL-
10/sIL-10R1 and the structure of sIL-10R2. The former,
stable complex was crystallized [21] and its structure was
determined [22]; however, all attempts to obtain stable
ternary complexes suitable for crystallization have so far
failed.
The known structures of binary and ternary cytokine-
receptor complexes show that although they differ from
each other in details, their overall organization is some-
what similar [22-29]. What is even more important, both
ligand/receptor and receptor/receptor binding sites are
located in topologically similar areas on the surface of the
interacting proteins and involve similar structural ele-
ments of the molecules (Table 1). For example, in the case
of the ligands, only two major receptor binding sites were
found, and both included topologically conserved N- and
C-terminal helices that form a left-handed four-helix bun-
dle [30], which is a signature element of all helical
cytokines, as well as loop AB. The difference was that in
some cases site I was used as a high-affinity receptor bind-
ing site, while in other cases site II was the one where the
high-affinity receptor was found to bind (Table 1). The
crystal structure of a binary complex of IL-10 with sIL-
10R1 showed that the high-affinity receptor binding site is
site I, and it is reasonable to assume that sIL-10R2 will
bind IL-10 in site II, making receptor/receptor contacts
similar to the already published structures of ternary
complexes.
We generated a structural model of the ternary complex of
IL-10 with its two soluble receptors, sIL-10R1 and sIL-
10R2. The model has been built on the assumption that
the structure of the binary IL-10/sIL-10R1 complex must
be preserved upon the binding of the second receptor
chain, the complex must possess twofold symmetry, and
that the structure of the complex of one domain of IL-10
with sIL-10R1 and sIL-10R2 should be somewhat similar
to the already known structures of ternary complexes hav-
ing two different receptor chains. To fulfill the latter
requirement, we took the structure of IL-6/IL-6Rα /gp130
[29] as an example.
Results
Structure of sIL-10R2
The structures of sIL-10R2 and sIL-10R1 appear to be very
similar (Fig. 1). They are both L-shaped molecules consist-
ing of two elongated N- and C-terminal domains (D1 and
D2), oriented at about 90° with respect to each other,
each having FBN-III-like topology [31-33]. Each domain
consists of seven β-strands organized in two antiparallel β-
sheets – A, B, E and C, C', F, and G – that pack one against
another in the shape of a sandwich. Loops L2-L4 of D1
and L5-L6 of D2 (Fig. 2) are involved in ligand binding.
Domains D1 and D2 of sIL-10R2 comprise 96 and 94
amino acid residues, respectively (residues 1–103 and
109–206), and are connected to each other by a 5 amino
acid-long linker (residues 104–108).
Deletions in the amino acid sequences of loops L2, L3 and
β-strand C' in domain D1 of sIL-10R2 (Fig. 3) make its
structure more compact than sIL-10R1. As a result, Tyr43,
which is a conserved residue in class II receptors [34], is
located a little higher than its counterpart in sIL-10R1.
Although in sIL-10R1 Tyr43 plays a very important role in
the interaction with the ligand, in sIL-10R2 it is located at
the very edge of the receptor/ligand interface. Cysteines 54
and 62 of sIL-10R2 form a disulfide bond that is con-BMC Structural Biology 2005, 5:10 http://www.biomedcentral.com/1472-6807/5/10
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served in class II receptors [32], linking β-strand C' with
the loop between the strand E and helix B. An equivalent
disulfide bridge in sIL-10R1 is formed between cysteines
54 and 35 [12,22], linking together β-strands C' and C
(Fig. 1).
Loop L3 of sIL-10R2 is two amino acids shorter in sIL-
10R1 and does not protrude out of the D1 domain as
much as in sIL-10R1. This alters the shape of the N-termi-
nal part of the interdomain region and makes it comple-
mentary to the surface of the ligand-binding site II. Tyr70
is shifted ~2.5 Å inside of the D1 domain to compensate
for the shortage of loop L3. In both receptors, the side
chain of Tyr70 participates in the formation of a hydro-
phobic core of the N-terminal domain. Deletions in
strand C' and loop L3 make the N-terminal domain of sIL-
10R2 about 3 Å shorter than in sIL-10R1.
β-strands F (residues 77–81) of both receptors contain a
conserved sequence (A/L)RVRA. Together with the
sequences HSDWV in sIL-10R2 and HSNWT in sIL-10R1
(residues 87–91), this motif makes an extended π-cation
system [35,36], usually found in the C-terminal domains
of the type I family of cytokine receptors [37]. In sIL-10R1,
a stacking structure is formed by His87, Arg80, Trp90,
Arg78, Trp48, and Leu41; and is about 19 Å in length,
which corresponds to roughly half of the domain length
(~ 36 Å). It connects β-strands C, C', F, and G, and stabi-
lizes the structure of the domain. In sIL-10R2, β-strand C'
is located away from the β-strand F, which makes it
impossible for the side chains of Phe48 and Leu41 to par-
ticipate in the formation of a π-cation system, consisting
in this case of only four residues – His87, Arg80, Trp90
and Arg78 – that keep together β-strands G and F.
Although the π-cation system of sIL-10R2 is only ~11 Å
long, which is about one-third of the total length of the
domain, it still may be important for the stability of the
structure of the domain. It is also likely that the π-cation
system may play a dual role during the lifetime of a
cytokine receptor. Mutagenesis studies of the erythropoie-
tin receptor revealed the importance of the π-cation sys-
tem for the transport of the receptor from endoplasmic
reticulum to the Golgi apparatus [38,39].
In comparison to D2 of sIL-10R1, D2 of sIL-10R2 has
three single amino acid deletions: Arg144, Pro154, and
Glu167, as well as a single insertion of Pro176A (Fig. 3).
The first deletion makes the connection between loop L5
and β-strand C shorter and moves the residues of loop L5
about 0.5 Å closer to the main body of the domain. Simi-
larly, deletions of Pro154 and Glu167 make the loops
connecting strands C and C' and strands C' and E slightly
shorter (Fig. 1). β-strands F and G are held together by a
disulfide bridge between Cys181 and Cys202, which is a
common feature for class II cytokine receptors. Insertion
of Pro176A in sIL-10R2 extends the loop between β-
strands E and F by about 3 Å, bringing this part of the D2
domain closer to the cell membrane.
Table 1: Positions of the cytokine-receptor binding sites in known structures of ternary and binary complexes.
Cytokine-receptor complexes (PDB 
code/reference)
Site I (Ligand/Receptor) Site II (Ligand/Receptor) Site III (Recept/Recept)
SSE* Ligand SSE* Receptor SSE* Ligand SSE* Receptor Contacting Domains
Ternary complexes
hGH/GHbp/GHbp (3HHR [23]) A, loop AB, D L1, L3-L6 A, C L1, L3-L6 D2-D2
hEPO/sEPOR/sEPOR (1EER [24]) A, loop AB, D L1-L6 A, C L1-L3, L5, L6 no interaction
oPL/srPRLR/srPRLR (1F6F [25]) A, loop AB, D L1-L6 A, C L1-L4 D2-D2
hIL6/sIL6Rα /gp130 (D1-D3) (1P9M [29]) A, D L2-L6 A, C L1-L3, L5 D2-D3
Binary complexes
hINF-γ /sINF-γ Rα ** (1FG9 [53]) A, loop AB, F' L2, L3, L5, L6
hLIF/gp130 (D2-D3) (1PVH [54]) A, C L2, L3, L5
G-CSF/G-CSFR (BN-BC) (1CD9 [27]) A, C L2-L6
hIL4/IL4-R1 (1IAR [26]) A, C L1-L6
hIL-10/sIL-10R1** (1J7V [22]) A, loop AB, F' L2-L6
cmvIL-10/sIL-10R1** (1LQS [55]) A, loop AB, F' L2-L6
vIL-6/gp130 (1I1R [56]) A, C L2, L3, L5
Ternary hIL-10 complex
hIL10/sIL10R1/sIL10R2**,*** A, loop AB, F' L2-L6 A, D L2, L3, L5, L6 D2-D2
(*)- SSE: Secondary structure elements.
(**)- In INF-γ and IL-10 structures helix F' is a topological equivalent of helix D of other helical cytokines.
(***)- Interface areas were calculated with program Surface (CCP4) using spherical probe of the radius 1.40 Å2.BMC Structural Biology 2005, 5:10 http://www.biomedcentral.com/1472-6807/5/10
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Hydrophobic patches on the surface and intermolecular 
hydrophobic clusters of the ternary IL-10/sIL-10R1/sIL-
10R2 complex
Both the ligand and receptor chains have several hydro-
phobic patches located on the surface of the molecules
(Table 2). Although the surface of IL-10 is mostly
hydrophilic, with 86% of hydrophobic residues involved
in the formation of the internal hydrophobic core [13], it
also has three solvent-exposed hydrophobic patches
(Table 2). Patch 1 is involved in the binding of sIL-10R1;
patch 2 interacts with both sIL-10R1 and sIL-10R2, while
patch 3 is located on the surface of helices A and D of IL-
10 and participates in interactions with sIL-10R2.
sIL-10R1 contains six hydrophobic patches, three in the
N-terminal domain and three in the C-terminal domain
(Table 2). Patches 1 and 2 are similar in size and located
on the opposite sides of the domain. Patch 1 is formed by
five residues coming from β-strands C' and E and helix B,
as well as three residues of the C-terminal domain flexible
loop connecting β-strand B and helix A. This is the largest
hydrophobic region in the first domain sIL-10R1, cover-
Stereo diagram of the superposition of sIL-10R1 and sIL-10R2 Figure 1
Stereo diagram of the superposition of sIL-10R1 and sIL-10R2. sIL-10R1 is green, sIL-10R2 is magenta, the disulfide bonds are 
shown in yellow.BMC Structural Biology 2005, 5:10 http://www.biomedcentral.com/1472-6807/5/10
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ing the surface of 475 Å2. Patch 2 is formed by seven resi-
dues coming from β-strands A, B, and E, and covers the
surface of 448 Å2. Thr25 is at the center of the patch and
although it is not a hydrophobic residue, its side chain is
oriented in such a way that Oγ 1 points inside the protein
molecule and forms a hydrogen bond with the main
chain nitrogen of Ser10, whereas Cβ and Cγ 2 atoms are
exposed to solvent. Patch 3 consists of three residues of
loop L2 and covers the surface of 207 Å2 in the interdo-
main region of sIL-10R1. Patch 4 consists of eight residues
covering the surface of 546 Å2 and is located close to the
C-terminus, near the area which is likely to be in contact
with the cellular membrane in vivo (Table 2). Patch 5
includes six residues coming from β-turn CC' and the first
half of β-strand C'. It covers the surface of 409 Å2 and has
an elongated shape. Patch 6 is formed by three residues of
loop L5 and covers 253 Å2 of the sIL-10R1 interdomain
region.
The pattern of hydrophobic patches of sIL-10R2 is similar,
although not identical, to that of sIL-10R1. sIL-10R2 has
seven patches, three in the N-terminal domain and four in
the C-terminal domain. Patch 1 lies at the top of the sIL-
10R2 N-terminal domain and is composed of 10 residues
covering the surface of 635 Å2. This is the largest hydro-
phobic solvent-exposed area on the surface of sIL-10R2.
Patches 2 and 3 (Table 2) cover 284 Å2 and 154 Å2, respec-
tively, and are located in the proximity of the ligand/
receptor interface. Patch 4 is formed by seven residues of
β-strands C' and E, filling the gap between the strands and
Topology diagram of a single ligand domain associated with high- and low-affinity receptors Figure 2
Topology diagram of a single ligand domain associated with high- and low-affinity receptors. β-strands of the receptor mole-
cules are shown as arrows and the helices are shown as rectangles. Binding loops of the receptor D1 domain are red and the 
loops of the D2 domain are blue. α-helices of single ligand domain are shown as circles. Helices A, B, C, and D (red) belong to 
one polypeptide chain of the ligand and helices E' and F' (green) belong to another polypeptide chain of the ligand. Highlighted 
helices (A, C, D, F') constitute the four-helix bundle that is involved in receptor binding.BMC Structural Biology 2005, 5:10 http://www.biomedcentral.com/1472-6807/5/10
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shielding the internal hydrophobic core of the molecule
from the solvent. The area of the patch is 572 Å2. Patch 5
is formed by four residues coming from the β-turn con-
necting strands A and B, and is 274 Å2 in size. Patches 4
and 5 are located at the very bottom of the C-terminal
domain and are likely to be in contact with the cellular
membrane. Patch 6 covers 203 Å2 and is located in the
central part of the receptor-receptor interface. Patch 7 con-
sists of only two residues that belong to loops L5 and L6.
It is 178 Å2 in size and is a part of the IL-10/sIL-10R2
interface.
Upon formation of the ternary complex, hydrophobic
patches from different molecules compensate each other,
creating intermolecular hydrophobic clusters inside of lig-
and-receptor and receptor-receptor interfaces (Table 2,
Fig. 4). Thus, one IL-10 domain complexed with two
receptor chains has two such clusters (1a and 2a, Fig. 4) in
the IL-10/sIL-10R1 interface, two clusters (1b and 2b) in
the IL-10/sIL-10R2 interface, and two clusters (1c and 2c)
in the sIL-10R1/sIL-10R2 interface. Intermolecular hydro-
phobic clusters found in the ternary IL-10/sIL-10R1/sIL-
10R2 complex are important elements that hold mole-
cules together after they have attracted each other by long-
range ionic interactions. It is worthwhile to note that
patch 1 and 2 of sIL-10R1 and patches 1, 3 and 4 of sIL-
10R2 remain exposed to solvent on the surface of the ter-
nary complex.
The structure of the IL-10/sIL-10R1/sIL-10R2 complex
The ternary complex of IL-10/sIL-10R1/sIL-10R2 is a two-
fold symmetrical molecule in which each of the domains
of IL-10 is bound with two receptor chains (Fig. 5). The
receptor chains are bound to adjacent sides on the surface
of a single IL-10 domain (Table 1). The sIL-10R1 binding
site (site I) is formed by helix A, loop AB, and helix F',
while the sIL-10R2 binding site (site II) is made by helices
A and D (Fig. 6). sIL-10R1 and sIL-10R2, bound to the
same IL-10 domain, interact with each other by their D2
domains, forming a receptor-receptor binding site (site III,
Fig. 6). The distance between C-termini of sIL-10R1 and
sIL-10R2 is 25.1 Å, which lies within the 25–32 Å range
found in the structures of other ternary complexes [23-
25,29]. The structure of the binary/intermediate complex
of IL-10/sIL-10R1 [22] is the same in the ternary complex.
We found only minor movements of some side chains
involved in the interactions with sIL-10R2 in sites II and
III. Both sIL-10R1 and sIL-10R2 receptor chains interact
with ligand loops L2-L6. Site III involves interactions
between residues coming from β-strands C, C', E, F and
loop L6 of sIL-10R1, and residues from β-strands A, B, E
and loop L5 of sIL-10R2 (Figs. 2, 6).
Structure-based sequence alignment of soluble receptors sIL-10R1 and sIL-10R2 Figure 3
Structure-based sequence alignment of soluble receptors sIL-10R1 and sIL-10R2. Aligned molecules have 20.4% of identical 
residues and 53.1% of homologous residues (red). Secondary structure elements are shown in green. Cysteines involved in 
disulfide bonds are highlighted in yellow, disulfide bonds are shown by black lines.BMC Structural Biology 2005, 5:10 http://www.biomedcentral.com/1472-6807/5/10
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Table 2: Hydrophobic patches of IL-10, sIL-10R1 and sIL-10R2
IL-10 Interaction site
Patch 1 
Residue 
Access. (%)
Surface area 189 Å2 
L46 L53 I145 A152
50 25 34 44
IL-10/sIL-10R1 interface,
with patch 3 of sIL-10R1
Patch 2 
Residue 
Access. (%)
Surface area 294 Å2 
H14 P16 P20 I158
73 66 71 25
IL-10/sIL10R1 interface, 
with patch 6 of sIL-10R1 
IL-10/sIL10R2 interface, 
with Patch 7 of sIL-10R2
Patch 3 
Residue 
Access. (%)
Surface area 183 Å2 
F36 A89 H90
33 86 45
IL-10/sIL-10R2 interface 
with Patch 2 (sIL-10R2)
IL-10R1 Domain D1
Patch 1 
Residue 
Access. (%)
Surface area 475 Å2 
I51 Y60 A64 V65 L67
18 39 90 34 46
M129 P131 A132
60 38 100
No interaction
Patch 2 
Residue 
Access. (%)
Surface area 448 Å2 
P6 P9 W12 T25 P26 P28 L58
45 45 45 39 56 65 56
No interaction
Patch 3 
Residue 
Access. (%)
Surface area 207 Å2 
Y43 G44 I45
44 66 83
IL-10/sIL10R1 interface, 
with patch 1 of IL-10
Domain D2
Patch 4 
Residue 
Access. (%)
Surface area 546 Å2 
I113 H114 G116 F117
60 56 47 58
L119 L172 G175 V177
41 84 61 69
sIL-10R1/sIL10R2 interface, 
with patch 5 of sIL-10R2
Patch 5 
Residue 
Access. (%)
Surface area 409 Å2
V153 P154 G155 F157 F159 H161
45 56 55 73 43 56
sIL-10R1/sIL10R2 interface, 
with patch 6 of sIL-10R2
Patch 6 
Residue 
Access. (%)
Surface area 253 Å2
H142 F143 A189
77 62 35
IL-10/sIL10R1 interface, 
with patch 2 of IL-10
IL-10R2 Domain D1
Patch 1 
Residue 
Access. (%)
Surface area 635 Å2
L2 G3 M4 P6 P7 A28
77 78 45 56 40 91
F29 G32 F83 A84
97 93 34 85
No interaction
Patch 2 
Residue 
Access. (%)
Surface area 284 Å2
L41 I47 F48
29 88 62
IL-10/sIL10R2 interface, 
with patch 3 of IL-10
Patch 3 
Residue 
Access. (%)
Surface area 154 Å2
C98 P98A V99
52 48 42
No interaction
Domain D2
Patch 4 
Residue 
Access. (%)
Surface area 572 Å2
F160 I162 F169 L172
73 26 12 71
L175 P176A W177
49 73 57
No interaction
Patch 5 
Residue 
Access. (%)
Surface area 274 Å2
V113 L114 A115 H119
47 62 100 40
sIL-10R1/sIL10R2 interface, 
with patch 4 of sIL-10R1
Patch 6 
Residue 
Access. (%)
Surface area 203 Å2
P107 L123 A124
69 65 54
sIL-10R1/sIL10R2 interface, 
with patch 5 of sIL-10R1
Patch 7 
Residue 
Access. (%)
Surface area 178 Å2
W143 P189
57 48
IL-10/sIL10R2 interface, 
with patch 2 of IL-10BMC Structural Biology 2005, 5:10 http://www.biomedcentral.com/1472-6807/5/10
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Site I interface (IL-10/sIL-10R1)
The interaction of IL-10 with sIL-10R1 in the ternary com-
plex is the same as that found in the crystal structure of the
intermediate/binary complex [22]. Briefly, the interface is
formed by the residues of the second half (middle and C-
terminal) of helix A, loop AB, and helix F' of IL-10, as well
as loops L2-L6 of sIL-10R1. Twenty-seven residues of the
ligand interact with 23 residues of the receptor chain, cre-
ating an extensive network of hydrogen bonds (70%)
(Table 3, Figs. 6A, 6B) and hydrophobic interactions
(30%) (Table 2). The total change in the accessible surface
for both IL-10 and sIL-10R1, calculated using a spherical
probe of the radius 1.40 Å, is about 2116 Å2. Thus, the
contact area between IL-10 and sIL-10R1 is about 1058 Å2.
The most important residues involved in receptor-ligand
binding are Pro20, Arg24, Arg27, Gln38, Glu42, Lys138,
Ser141, Asp144, Glu151, and Ile158 of IL-10 and Tyr43,
Arg76, Arg96, Phe143, Ser190 and Arg191 of the sIL-10R1
[22]. The IL-10/sIL-10R1 interface includes two hydro-
phobic clusters located at the top and at the bottom of the
interface (Table 2, Fig. 4).
Site II interface (IL-10/sIL-10R2)
The interface of site II is formed by helix A, loop CD, and
helix D of IL-10, as well as by loops L2, L3, L6, and α-helix
A of the sIL-10R2 (Table 2, Figs. 6A, 6C). Helix A interacts
with loops L3, L6, and helix A, whereas helix D interacts
with loop L2 of sIL-10R2. Site II is smaller than site I; its
total surface is 568 Å2, which is only 54% of the surface of
site I. IL-10 and sIL-10R2 each donate 13 residues to the
interface. Interacting residues are mostly polar (~80%)
and link the ligand to the receptor via hydrogen bonds
(Table 3) and hydrophobic interactions (Table 2). The
most important interface residues are Pro16, Asn18,
Asn21, Arg24, Asp28, Arg32, Glu81, Ala89, His90, and
Asn92 of IL-10 and Arg46, Ile47, Ser68, Lys69, Thr133,
Asn138, Ser142, Trp143, and Arg191 of sIL-10R2. Most
interactions occur between IL-10 helix A and loops L3 and
L6 of sIL-10R2, with only a few contacts between IL-10
helix D and loop L2 of the sIL-10R2. Arg24 of IL-10 occu-
pies a unique position in the complex. Its side chain
projects down towards the cell membrane along the
receptor-receptor interface and forms hydrogen bonds
with the carbonyl oxygen of Val188 of sIL-10R1 and the
side-chain atom Oδ 1 of Asn138 of sIL-10R2, linking both
receptor chains together. The IL-10/sIL-10R2 interface
Stereo diagram of intermolecular hydrophobic clusters of the ternary IL-10/sIL-10R1/sIL-10R2 complex Figure 4
Stereo diagram of intermolecular hydrophobic clusters of the ternary IL-10/sIL-10R1/sIL-10R2 complex. Polypeptide chains of 
IL-10 are shown in orange and cyan, sIL-10R1 is green, and sIL-10R2 is magenta. Side chains of the residues that constitute 
hydrophobic clusters are shown in blue. Clusters 1a and 2a are the "top" and the "bottom" hydrophobic regions of IL-10/sIL-
10R1 interface, clusters 1b and 2b are the "top" and the "bottom" hydrophobic regions of IL-10/sIL-10R2 interface and clusters 
1c and 2c are the "top" and the "bottom" hydrophobic regions of sIL-10R1/sIL-10R2 interface. Disulfide bonds are shown in 
yellow. The potential glycosylation sites are shown in red.BMC Structural Biology 2005, 5:10 http://www.biomedcentral.com/1472-6807/5/10
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also includes a hydrophobic cluster located at the bottom
part of the interface, formed by Pro16 of the ligand and
Trp143 of the receptor. The upper part of the IL-10/sIL-
10R2 interface also includes a hydrophobic cluster
formed by Ala89 and His90 of IL-10, and I47 of sIL-10R2.
Unlike in the cluster 2c (Fig. 4), the hydrophobic area 1c
is weaker but still is an important element of the IL-10/
sIL-10R2 interface. A smaller interface area and a reduced
amount of interacting residues reflect the low affinity of
the sIL-10R2 towards its binding partners.
Site III interface (sIL-10R1/sIL-10R2)
The interface between sIL-10R1 and sIL-10R2 is formed by
residues that belong to β-strands C, C', E, and F of sIL-
10R1 and by residues of β-strands A, B, E, and loop L5 of
sIL-10R2 (Tables 2, 3; Fig. 6D). The surfaces of C-terminal
domains of the receptors are complementary. Within 3.8
Å distance cutoff, receptors 1 and 2 donate 15 and 13 res-
idues, respectively, to form a contact area that is com-
posed of 65% hydrophilic and 35% hydrophobic residues
and is about 803Å2 in size (Tables 2, 3). The most impor-
tant residues are Gly116, Phe117, Glu145, Glu147,
His161, Lys162, Lys165, His166, Ser170, Leu172,
Gly175, and Lys185 of sIL-10R1, and Gln110, Leu114,
His119, Arg121, Leu123, Ala124, Lys126, Glu132,
Asn138, Asn141, and Tyr166 of sIL-10R2. The contact
area between two receptors can be divided into three
parts. The upper part of site III is hydrophilic and contains
a wide network of hydrogen bonds. Almost all residues
that are located in this area are hydrophilic. The middle
Stereo diagram of the ternary complex of human IL-10/sIL-10R1/sIL-10R2 Figure 5
Stereo diagram of the ternary complex of human IL-10/sIL-10R1/sIL-10R2. Polypeptide chains of IL-10 are shown in orange and 
cyan, sIL-10R1 is green, sIL-10R2 is magenta. The hypothetical cell membrane is perpendicular to the plane of the figure on the 
right and the twofold symmetry axis (not shown) is horizontal.BMC Structural Biology 2005, 5:10 http://www.biomedcentral.com/1472-6807/5/10
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Stereo diagram of each interface within a single IL-10/sIL-10R1/sIL-10R2 signaling unit (panel A) Figure 6
Stereo diagram of each interface within a single IL-10/sIL-10R1/sIL-10R2 signaling unit (panel A). Polypeptide chains of IL-10 are 
shown in orange and cyan. sIL-10R1 is green and sIL-10R2 is magenta. Panels B, C and D represent close-up view of each inter-
face, including contact residues. (B)- an interface between IL-10 and sIL-10R1, (C)- an interface between IL-10 and sIL-10R2, 
(D)- an interface between sIL-10R1 and sIL-10R2. Intermolecular hydrogen bonds calculated with in 3.2 Å distance cutoff are 
shown as blue dotted lines.BMC Structural Biology 2005, 5:10 http://www.biomedcentral.com/1472-6807/5/10
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part of the interface has a roughly equal number of
charged and uncharged residues, while the lower part of
the receptor/receptor interface is almost solely hydropho-
bic, with an intermolecular hydrophobic cluster at the
bottom of C-terminal domains of the receptors (Figs. 4,
6).
Glycosylation sites
The receptors sIL-10R1 and sIL-10R2 contain six and four
potential N-linked glycosylation sites, respectively (Fig.
4). In the complex, all sites are fully exposed to the solvent
and are not part of receptor-ligand or receptor-receptor
interfaces. Moreover, each particular potential carbohy-
drate-binding site is located at a sufficient distance from
the interfaces, which eliminates the possibility of a sugar
Table 3: Intermolecular hydrogen bonds of the IL10/sIL10R1/sIL10R2 complex
IL-10-IL-10R1 interface
IL-10 SSE IL-10R1 SSE Distance Å
R24L NE A R191R O L6 3.0
R24L NH1 A V188R O L6 2.9
R24L NH1 A R191R O L6 3.0
R27L NE A S190R O L6 2.9
R27L NH1 A D100R OD2 L4 3.2
K34L NZ A D100R OD1 L4 2.9
Q38L OE1 A R96R N L4 3.0
D41L O loop AB R76R NH1 L3 2.9
Q42L O loop AB R76R NH2 L3 3.0
D44L OD1 loop AB R76R NH2 L3 2.8
D44L O loop AB G44R N L2 2.9
N45L N loop AB E46R OE2 L2 3.0
K138S NZ F' Y43R OH L2 2.8
S141S O F' R96R NH2 L4 2.9
D144S OD1 F' R96R NH2 L4 2.8
D144S OD2 F' R96R NH2 L4 3.0
E151S OE1 F' R191R NH1 L6 2.9
E151S OE2 F' R191R NH1 L6 2.8
E151S OE1 F' R191R NH2 L6 2.9
IL-10-IL-10R2 interface
N18L OD1 A R191A NH1 L6 2.7
N18L ND2 A S142A OG1 L6 2.7
N21L ND2 A N138A O α A2 . 8
R24L NH2 A N138A OD1 α A2 . 7
R24L NH2 A T133A O loop Bα A3 . 1
D28L OD1 A K69A NZ L3 2.8
D28L OD2 A K69A NZ L3 3.0
D28L O A K69A NZ L3 3.2
R32L NH1 A S68A OG L3 3.3
E81L OE2 loop CD R46A NH2 L2 3.3
N92L OD1 D R46A NH1 L2 2.8
IL-10R1-IL-10R2 interface
E145R OE1 C N138A OD1 L5 3.2
E145R OE2 C N141A ND2 L5 2.7
E147R OE2 C K126A NZ loop Bα A3 . 2
H161R NE2 C' A124A O loop Bα A2 . 9
K162R NZ C' Q110A OE1 A 2.6
K165R NZ loop C'E N141A OD1 L5 2.7
H166R NE2 loop C'E Y166A OH loop C'E 3.0
S170R OG E R121A NH1 B 3.1
S170R O E R121A NH1 B 2.6
K185R NZ F E132A OE2 loop Bα A3 . 2
(*)- SSE: Secondary structure elements. (**)- In INF-γ and IL-10 structures helix F' is a topological equivalent of helix D of other helical cytokines. 
(***)- Interface areas were calculated with program Surface (CCP4) using spherical probe of the radius 1.40 Å2.BMC Structural Biology 2005, 5:10 http://www.biomedcentral.com/1472-6807/5/10
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chain clashing with a neighboring protein molecule. In
sIL-10R1, Asn29 flanks the top end of the receptor N-ter-
minal domain, whereas Asn53 and Asn89 are in the cen-
tral part of the domain. They are located on loop BC, β-
strand C', and in the region between β-strands G1 and G2,
respectively. The N-terminal domain of sIL-10R2 also has
three potential glycosylation sites: Asn33, Asn56, and
Asn92. Asn33 is located close to the N-terminal end of the
domain, whereas Asn56 and Asn92 are found in the cen-
tral part of the domain, on the opposite sides of a β-sand-
wich.
The C-terminal domain of sIL-10R1 contains three poten-
tial glycosylation sites at Asn133, Asn156, and Asn168,
located near the α-helix A, on β-turn CC', and at the begin-
ning of β-strand E (Figs. 2, 4), respectively. The site at
Asn133 is located near the N-terminal end of the domain,
close to the interdomain region of sIL-10R1. Asn156 is at
the bottom of the C-terminal domain, while the
oligosaccharide attached to Asn168 is in the central part of
domain D2. In the ternary complex, this residue is likely
to be in contact with the cellular membrane. The C-termi-
nal domain of sIL-10R2 has only one potential carbohy-
drate site, Asn153, which is close to the C-terminus of the
receptor. This residue is a part of β-turn CC' and is very
close to position Asn156 of sIL-10R1 upon superposition
of the receptor chains.
Discussion
It is clear that the quality of any theoretical model should
be assessed based on its agreement with experimental data
such as, for example, mutagenesis. Unfortunately, we
were unable to find any such data for the IL-10/IL-10R1/
IL-10R2 complex, either in literature or as personal com-
munications. Therefore, to evaluate the correctness of the
model, we can only rely on the commonly accepted crite-
ria: the model is in the global minimum of energy; general
similarity to other ternary complexes of cytokines; usage
of similar, well defined receptor binding sites on the sur-
face of the ligand (Table 1); and correlation between the
available kinetic binding data and intermolecular binding
surfaces and contacts. As we have already mentioned, a
general similarity of the ternary IL-10 complex to known
structures of other ternary complexes and involvement of
the similar ligand binding sites have been postulated from
the beginning; thus, these conditions have been necessar-
ily satisfied. The model of the ternary complex does corre-
spond to the minimum of the energy, and the pattern of
the interactions of sIL-10R2 with the binary IL-10/sIL-
10R1 complex agrees well with its low affinity nature.
Recent study of binding of IL-10 to IL-10R2 by peptide
scans [40] showed that, although IL-10R2 did not form a
binary complex with IL-10, it recognized regions of helix
A and loop AB of IL-10 (amino acid residues 19–43) when
they were presented as 15-mer peptides. In our model, the
IL-10/IL-10R2 interface includes residues 18–32 of IL-10
(Table 3). Among the residues involved in creating the IL-
10R1/IL-10R2 interface, seven residues of IL-10R1 have
the same residue type as residues 33–43 of IL-10 (Table 2,
Table 3). This may explain the necessity of formation of
IL-10/IL-10R1 binary complex before IL-10R2 can join
and complete the ternary signaling complex.
IL-10 binds to the receptor chains via two sites located on
the adjacent sides of its four-helix bundle [30]. Site I is
formed by helices A and F', whereas site II is formed by
helices A and D (Table 1). Both receptor chains interact
with IL-10 through their cytokine recognition motifs,
which consist of the loops and β-turns of the receptor
interdomain region connecting consecutive antiparallel β-
strands [22-29]. Typically, the low-affinity receptor can-
not bind to a ligand by itself. Its association occurs via a
cooperative binding site that is formed by both the ligand
and the high-affinity receptor. With the exception of the
prolactin ternary complex, C-terminal domains of the
receptors contact each other in the vicinity of the cellular
membrane (Table 1). Such interaction brings the intracel-
lular parts of the receptors together, resulting in activation
of signal transduction.
Receptor chains of the ternary IL-10 complex interact with
each other via β-strands C, C', E, and F of sIL-10R1 and β-
strands E, B, A, and loop L5 of sIL-10R2, forming an inter-
face between the sides of their C-terminal domains Tables
(2, 3; Figs. 4, 5, 6). The distance between the Cα atoms of
the C-termini of IL-10R1 and IL-10R2 is 25.1 Å. In the
known structures of other ternary complexes, the
distances between the Cα atoms of the last residues of the
extracellular parts of the receptor chains vary between 25
and 32 Å.
The surfaces of IL-10 and of both the sIL-10R1 and sIL-
10R2 receptors contain several hydrophobic patches
(Table 2). In the ternary complex, most of these areas face
each other to form intermolecular hydrophobic clusters.
Each interface contains two such areas that flank opposite
sides of contact regions (Fig. 4). The bottom clusters of IL-
10/sIL-10R1 and IL-10/sIL-10R2 touch each other at the
point where the ligand and both receptors join, creating a
larger hydrophobic area formed by all three molecules.
Such a cluster is not observed in other structures of ternary
complexes and is, therefore, unique for the ternary IL-10
complex.
Both receptors have several potential glycosylation sites,
which are located on protein surfaces in places where they
do not conflict with the three-dimensional organization
of the IL-10/sIL-10R1/sIL-10R2 complex (Fig. 4). The role
of carbohydrates in forming and maintaining cytokine/
receptor complexes is not well understood. It was shownBMC Structural Biology 2005, 5:10 http://www.biomedcentral.com/1472-6807/5/10
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that the granulocyte-macrophage colony-stimulating fac-
tor (GM-CSF) receptor α subunit requires N-glycosylation
for binding and signaling [41]. Tunicamycin treatment
inhibited GM-CSF binding in a dose-dependent manner,
with a maximum of 85% inhibition at 3 µg/ml. Treatment
of human leukemia HL-60 cells with tunicamycin com-
pletely blocked GM-CSF-induced tyrosine phosphoryla-
tion, which suggests that N-glycosylation of the receptor is
necessary for intracellular signaling [41]. However, the
non-glycosylated mutant of sIL-10R1 is capable of form-
ing a stable binary complex with IL-10 [22]. GM-CSF is a
glycoprotein in which glycosylation is not required for its
biological activity. GM-CSF that is expressed in E. coli and
thus, not glycosylated, retains full activity [42]. By con-
trast, the IL-10R2 binding region on IL-22 contains an N-
linked carbohydrate that is likely important for binding
[43]. Similarly, N-linked glycosylation of viral IL-6 is
shown to increase gp130 binding and biological activity
[44]. Taking into account that no carbohydrates are
involved in the intermolecular interactions in the ternary
IL-10/sIL-10R1/sIL-10R2 complex, as well as the fact that
deglycosylated sIL-10R1 can form a quite stable binary
complex with the IL-10, we may conclude that N-linked
oligosaccharides are not essential for the formation of the
biologically active ternary IL-10/IL-10R1/IL-10R2 com-
plex. It is clear that more structural data are required to
address the question of why some cytokines and their
receptors depend upon the presence of carbohydrates,
whereas others do not.
It was shown that a series of anti-human IL-10 antibodies
can efficiently neutralize this cytokine [45]. Based on the
recognition epitope, antibodies can be divided into three
groups, A, B and C. The epitopes were identified using IL-
10-derived, overlapping peptide scans prepared by spot
synthesis. Antibodies of group A inhibit biological activity
of IL-10 in an approximately equimolar ratio, at concen-
trations as low as 10 pM [45]. It has been shown that
monoclonal antibody CB/RS/2 recognizes two binding
regions of a discontinuous epitope on the surface of the
molecule that comprises the N-terminal half of helix A
and helix D [46]. Thus, this antibody binds to site II of the
ligand and prevents IL-10 from association with its low-
affinity receptor. An overlapping peptide scan technique
has also been used for mapping IL-10 residues that bind
to sIL-10R1, as well as mapping the residues of sIL-10R1
that interact with the ligand [47]. It was shown that resi-
dues of helices A and C of the ligand interact with the res-
idues of loops L3-L6 of the high-affinity receptor. The
structure of the IL-10/sIL-10R1 complex confirmed those
results [22]. However, no mapping data exist for the resi-
dues that form the IL-10/sIL-10R2 interface. Such data
would be very valuable to guide the design of biochemical
experiments.
In the absence of sIL-10R1, IL-10 cannot bind to sIL-10R2,
and the two receptor chains cannot interact with each
other without a ligand. Therefore, assembly of the ternary
complex consists of two steps. In the first step, IL-10 binds
to sIL-10R1, forming a binary complex; subsequently, sIL-
10R2 binds to the preformed IL-10/sIL-10R1 complex,
completing the ternary complex. Such differences in bind-
ing abilities could be linked to the physical characteristics
of the corresponding interfaces. The area of site I (1058
Å2) is about 25–45% larger than the areas of site II (568
Å2) and site III (803 Å2). The number of residues involved
in interface formation is also larger for the IL-10/sIL-10R1
contact region. Site I is formed by a total of 50 residues,
whereas sites II and III are composed of 26 and 28 resi-
dues, respectively. However, when combined together,
sites II and III have an area and number of charged and
hydrophobic interactions comparable to those of site I,
which may explain the ability of the low-affinity receptor
to bind to a preformed ligand-high-affinity receptor com-
plex. This is also true if we compare the areas of binding
sites I, II and III in other ternary complexes of cytokines
such as GH, PL, EPO, and IL-6; there, the area of site I is
usually larger than each of the areas of site II or III,
whereas combined area of sites II and III are roughly equal
to or larger than the area of site I [23,25,24,29].
Methods
The model of sIL-10R2, the low-affinity receptor, was gen-
erated using the published crystal structure of sIL-10R1 as
a template (pdb code 1J7V ([22]). The original amino acid
sequence of sIL-10R1 was mutated to that of sIL-10R2 in
accordance with the alignment of their sequences shown
in Figure 3 (20.4% identity and 53.1% similarity) [34,48].
Model building was followed by energy minimization,
which included 500 cycles of positional refinement to
optimize stereochemistry of newly built parts of the struc-
ture, followed by simulated annealing slow cool protocol
and another 500 cycles of positional refinement. To pre-
serve the overall fold, a 2.8 kcal/mole restraint has been
imposed on all Cα atoms of the model. All other main
and side-chain atoms were allowed to move freely within
the appropriate stereochemical parameters.
A model of the ternary complex of one domain of IL-10
with sIL-10R1 and sIL-10R2 was generated on the
assumption that the structure of the intermediate binary
complex IL-10/sIL-10R1 does not change much upon
binding of the second receptor chain, sIL-10R2, and that
mutual arrangement of ligand and receptor chains is sim-
ilar to what was found in the crystal structure of IL-6/IL-6-
Rα /gp130 [29]. At the first step, the Cα atoms of the
structure of one domain of IL-10 complexed with sIL-
10R1 were superimposed onto Cα atoms of IL-6/sIL-6Rα,
and then the structure of sIL-10R2 was superimposed
onto gp130. Subsequently, the best fit of charge comple-BMC Structural Biology 2005, 5:10 http://www.biomedcentral.com/1472-6807/5/10
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mentarity of sIL-10R2 to the intermediate binary complex
was achieved upon superposition of the C-terminal
domain of sIL-10R2 with the C-terminal domain of
gp130, followed by rotation of sIL-10R2 as a whole
around the axis perpendicular to the cell surface and pass-
ing through the center of mass of the IL-10 domain, fol-
lowed again by translation along the surface of helices A
and D. The second half of the hexameric IL-10/sIL-10R1/
sIL-10R2 complex was generated by applying twofold
symmetry (Fig. 5). Model building was followed by the
energy minimization procedure under conditions
described above until the drop in total energy between
consecutive refinement steps was less than 1%. Root
mean square deviations in positions of Cα atoms for IL-
10, sIL-10R1 and sIL-10R2 in the ternary complex before
and after energy minimization were 0.38 Å, 0.40 Å and
0.45 Å, respectively.
Sequence alignment was performed with program CLUS-
TALW 1.74 [48], model building with program CHAIN
[49], and energy minimization with XPLOR 3.1 [50]; all
superpositions were performed with program LSQKAB
from CCP4 [51]. Figures 1, 4, and 6 were generated with
program SETOR [52], while Figure 5 was generated with
the program pyMOL (DeLano W.L. The PyMOL Molecular
Graphics System 2002, DeLano Scientific, San Carlos, CA,
USA).
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